Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.00%
)
US TECH 100
24,038.40
(
-0.39%
)
Dow Jones
46,993.26
(
0.00%
)
Brent Oil
104.75
(
4.07%
)
Bitcoin
72,512.28
(
-1.93%
)
News Focus
News Focus

Replies to post #79025 on Biotech Values

Replies to #79025 on Biotech Values
icon url

genisi

06/04/09 12:56 PM

#79038 RE: DewDiligence #79025

Trial should take over a year and CLS's C1 inhibitor could be approved very soon and block Cinryze for acute due to orphan exclusivity.
icon url

genisi

10/12/09 9:21 AM

#84894 RE: DewDiligence #79025

As CSL’s Berinert is approved first for the treatment of acute HAE, it will block Cinryze from the market for this indication in the US for 7 years, due to its orphan drug status.